Table 1.
Tabular representation of drugs and their corresponding clinical trial information.
| Drug | Target | Clinical Trial ID | Number of Patients | Phase | Result |
|---|---|---|---|---|---|
| Birinapant | IAPs | NCT01681368 | 11 | 2 | SD = 2 (18.2 %) upto 4-5 months CR = 0 PR = 0 |
| Birinapant | IAPs | NCT01940172 | 18 | 1 | PR = 1 SD = 4 |
| DEBIO1143 | IAPs | NCT01930292 | 11 out of 31 with ovarian cancer | 1 | PR = 4 (36.4%) SD = 4 (36.4%) PD = 3 (27.2%) Terminated |
| PRIMA-1MET | P53 | NCT02098343 | 200 | 1 & 2 | Ongoing |
| Alisertib | Aurora kinase (PI3K/Akt/mTOR pathway) | NCT01091428 | 191 and 142 respectively | 1 & 2 | median PFS increased by 2 months |
| Alisertib | Aurora kinase (PI3K/Akt/mTOR pathway) | NCT00853307 | 31 | 2 | CR = 3 (10%) PR = 4 (31%) SD = 7 (23%) PD = 12 (40%) NE = 5 (16.1%) |
| Crizotinib | MET/ALK/ROS1 | NCT02465060 | 7/635 with MET amplification (ovarian cancer) | 2 | Ongoing |
| Crizotinib | MET/ALK/ROS1 | NCT02568267 | 300 patients with different types of cancer | 2 | Ongoing |
| Cabozantinib | MET | NCT00940225 | 70 | 2 | PR = 14 (20%) OS = 50% at 12 weeks PFS= 5.9 months |
| Cabozantinib | MET | NCT02315430 | 13 | 2 | Results awaited |
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, OS = overall survival, PFS = Platinum free survival, and NE = inevaluable, IAPs = inhibitor of apoptotic proteins, PI3K = phosphatidylinositol 3-kinase, mTOR = mammalian target of rapamycin, MET = mesenchymal-epithelial transition factor, ALK = anaplastic lymphoma kinase, ROS1 = ROS proto-oncogene 1.